Investigational drug · Phase 2
Adeno-associated virus vector expressing a human RPGR gene
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for X-Linked Retinitis Pigmentosa (XLRP).
Phase 2Last checked: Nov 20, 2026Latest source record: Jun 25, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
5
Any phase or sponsor naming "Adeno-associated virus vector expressing a human RPGR gene"
First trial start
2025
Sep 10, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Adeno-associated virus vector expressing a human RPGR gene", any sponsor or status.
Conditions studied
As listed on its trial records.
- X-Linked Retinitis Pigmentosa (XLRP)
Approved drugs for the same conditions: Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "Adeno-associated virus vector expressing a human RPGR gene" as an intervention, largest first.
- A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRPPivotal-lookingActive, not recruiting
Beacon TherapeuticsIndustry
NCT04850118 · 85 participants · Start Mar 14, 2024 · Primary completion Jun 30, 2026
Drug: rAAV2tYF-GRK1-hRPGRco; Control · For: X-Linked Retinitis Pigmentosa
Sites: Scottsdale, Arizona; Los Angeles, California; Jacksonville, Florida · 25 sites in all
- Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR MutationsActive, not recruiting
Beacon TherapeuticsIndustry
NCT03316560 · 29 participants · Start Apr 16, 2018 · Primary completion Nov 9, 2023
Drug: rAAV2tYF-GRK1-RPGR · For: X-Linked Retinitis Pigmentosa
Sites: Durham, North Carolina; Cincinnati, Ohio; Portland, Oregon · 4 sites in all
- A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN)Enrolling by invitation
Beacon TherapeuticsIndustry
NCT06275620 · 24 participants (planned) · Start Nov 14, 2023 · Primary completion Nov 2025
Drug: AGTC-501 (high dose and standard corticosteroid regimen); AGTC-501 (low dose and standard corticosteroid regimen) and 1 more · For: X-Linked Retinitis Pigmentosa
Sites: Jacksonville, Florida; Miami, Florida; Boston, Massachusetts · 7 sites in all
- A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE)Active, not recruiting
Beacon TherapeuticsIndustry
NCT06333249 · 14 participants · Start Apr 13, 2021 · Primary completion Apr 11, 2023
Drug: rAAV2tYF-GRK1-RPGR · For: X-Linked Retinitis Pigmentosa
Sites: Jacksonville, Florida; Boston, Massachusetts; Cincinnati, Ohio · 6 sites in all
- A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis PigmentosaActive, not recruiting
Beacon TherapeuticsIndustry
NCT07174726 · 10 participants (planned) · Start Sep 10, 2025 · Primary completion Dec 31, 2029
Drug: Adeno-associated virus vector expressing a human RPGR gene · For: X-Linked Retinitis Pigmentosa (XLRP)
Sites: Jacksonville, Florida; Miami, Florida; Durham, North Carolina · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.